Sterol regulatory element-binding protein 1 is required for ovarian tumor growth

Nie,Long-Yun; Lu,Qing-Tao; Li,Wei-Hua; Yang,Ning; Dongol,Samina; Zhang,Xin; Jiang,Jie

doi:10.3892/or.2013.2575

Sterol regulatory element-binding protein 1 is required for ovarian tumor growth

Authors:
- Long-Yun Nie
- Qing-Tao Lu
- Wei-Hua Li
- Ning Yang
- Samina Dongol
- Xin Zhang
- Jie Jiang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China, Department of Pharmaceutical Chemistry, Shandong University of Traditional Chinese Medicine, Jinan 250012, P.R. China
Published online on: June 28, 2013 https://doi.org/10.3892/or.2013.2575
Pages: 1346-1354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Re-programming of lipogenic signaling is one of the most significant alterations of tumor cell pathology. Consistent with a large demand for lipids, tumor cells express high levels of lipogenic enzymes, most of which are transcriptional targets of sterol regulatory element-binding protein 1 (SREBP1). However, the expression levels and the function of SREBP1 in ovarian cancer are largely unknown. Our study aimed to assess the oncogenic potential of SREBP1 in ovarian cancer. In this study, we showed that the SREBP1 protein expression was significantly higher in human ovarian cancer compared to benign and borderline ovarian tumors by immunohistochemical staining. Knockdown of SREBP1 by small hairpin RNA (shRNA) in ovarian cancer cells retarded cell growth, migration and invasion and enhanced cell apoptosis without significant effects on cell cycle distribution. In a xenograft SCID mouse model, SREBP1 silencing inhibited tumor growth in vivo and reduced the expression of SREBP1 downstream lipogenic genes at both the protein and mRNA levels. Taken together, the results from this study demonstrate a crucial role of SREBP1 in ovarian cancer growth, which establish SREBP1 as a novel therapeutic target for antitumor therapy.

View Figures

View References

1	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
2	Medes G, Thomas A and Weinhouse S: Metabolism of neoplastic tissue. IV A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 13:27–29. 1953.PubMed/NCBI
3	Horton JD: Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans. 30:1091–1095. 2002. View Article : Google Scholar : PubMed/NCBI
4	Wang X, Sato R, Brown MS, Hua X and Goldstein JL: SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell. 77:53–62. 1994. View Article : Google Scholar : PubMed/NCBI
5	Horton JD and Shimomura I: Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol. 10:143–150. 1999. View Article : Google Scholar : PubMed/NCBI
6	Brown MS and Goldstein JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89:331–340. 1997. View Article : Google Scholar : PubMed/NCBI
7	Osborne TF: Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem. 275:32379–32382. 2000. View Article : Google Scholar : PubMed/NCBI
8	Edwards PA, Tabor D, Kast HR and Venkateswaran A: Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta. 1529:103–113. 2000. View Article : Google Scholar : PubMed/NCBI
9	Yang YA, Morin PJ, Han WF, Chen T, Bornman DM, Gabrielson EW and Pizer ES: Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res. 282:132–137. 2003. View Article : Google Scholar : PubMed/NCBI
10	Li JN, Mahmoud MA, Han WF, Ripple M and Pizer ES: Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res. 261:159–165. 2000. View Article : Google Scholar : PubMed/NCBI
11	Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W and Verhoeven G: Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol. 92:273–279. 2004. View Article : Google Scholar : PubMed/NCBI
12	Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F and Evert M: Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 140:1071–1083. 2011. View Article : Google Scholar : PubMed/NCBI
13	Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, Gu Z, Weifang D and Yongliang G: Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res. 18:233–239. 1999.PubMed/NCBI
14	Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T and Kaneko S: Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol. 50:100–110. 2009. View Article : Google Scholar : PubMed/NCBI
15	Swinnen JV, Brusselmans K and Verhoeven G: Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 9:358–365. 2006. View Article : Google Scholar : PubMed/NCBI
16	Mukherjee A, Wu J, Barbour S and Fang X: Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. J Biol Chem. 287:24990–25000. 2012. View Article : Google Scholar : PubMed/NCBI
17	Uddin S, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, Bavi P and Al-Kuraya KS: Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and its inhibition potentiates cisplatin-induced apoptosis. Mol Med. 17:635–645. 2011. View Article : Google Scholar
18	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
19	Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL and Schulze A: SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8:224–236. 2008. View Article : Google Scholar : PubMed/NCBI
20	Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene. 22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
21	Krycer JR, Sharpe LJ, Luu W and Brown AJ: The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab. 21:268–276. 2010. View Article : Google Scholar : PubMed/NCBI
22	Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K and Ishikawa Y: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 68:8547–8554. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zu XY, Zhang QH, Liu JH, Cao RX, Zhong J, Yi GH, Quan ZH and Pizzorno G: ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat Anticancer Drug Discov. 7:154–167. 2012. View Article : Google Scholar : PubMed/NCBI
24	Luo DX, Tong DJ, Rajput S, Wang C, Liao DF, Cao D and Maser E: Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential. Recent Pat Anticancer Drug Discov. 7:168–184. 2012. View Article : Google Scholar : PubMed/NCBI
25	Wang C, Rajput S, Watabe K, Liao DF and Cao D: Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci. 2:515–526. 2010. View Article : Google Scholar : PubMed/NCBI
26	Tong L and Harwood HJ Jr: Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J Cell Biochem. 99:1476–1488. 2006. View Article : Google Scholar : PubMed/NCBI
27	Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madireddi MT, Lawrence RM, Wong TW and Rupnow BA: Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res. 9:1551–1561. 2011. View Article : Google Scholar : PubMed/NCBI
28	Igal RA: Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis. 31:1509–1515. 2010. View Article : Google Scholar : PubMed/NCBI
29	Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, Avances C, Allory Y, de la Taille A, Culine S, Blancou H, Cristol JP, Michel F, Sardet C and Fajas L: Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther. 9:1740–1754. 2010. View Article : Google Scholar : PubMed/NCBI
30	Liu H, Liu JY, Wu X and Zhang JT: Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol. 1:69–89. 2010.PubMed/NCBI
31	Mashima T, Seimiya H and Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 100:1369–1372. 2009. View Article : Google Scholar : PubMed/NCBI